

20 September 2022

Immune Thrombocytopenia and Patients Treated with Revolade, Nplate, Doptelet and Tavlesse

1. How many patients has your Trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the treatments listed below:

• Revolade (eltrombopag)	Eltrombopag	28
• Nplate (romiplostim)	Romiplostim	<5
• Doptelet (avatrombopag)	Avatrombopag	<5
• Tavlesse (fostamatinib)	Fostamatinib	<5

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. In the last 6 months (or the latest 6 months data you have available), how many patients has your Trust treated for Immune Thrombocytopenia (ITP)?

110

3. Of the patients treated for Immune Thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

- Rituximab
- Mycophenolate mofetil
- Surgery (splenectomy)

This information is not readily available, as it is not held centrally. The Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

20 September 2022

- 4. Does your Trust participate in any ongoing clinical trials for Immune Thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?**

Belfast Trust is not participating in any ongoing clinical trials for Immune Thrombocytopenia.